Abstract
Pulmonary oedema (PO) can emerge from mechanical disorders in pulmonary circulation leading to elevated fluid filtration in the lung, or from increased vascular permeability due to inflammatory or toxic injury of the alveolarcapillary barrier. A number of these disorders causing PO is associated with increased catecholamine (CA) levels in plasma and lung tissue and/or increased sympathetic activation such as neurogenic PO, high-altitude PO or PO in patients with phaeochromocytoma. Experimental CA stimulation in animals induced PO after less than one hour of infusion. Both α- and β-adrenergic mechanisms are involved in the pathogenesis but also in the resolution of PO. CAs increase pulmonary capillary pressure and thus, enhance fluid filtration into the pulmonary interstitium. Additionally, by activation of proinflammatory cytokines, they induce pulmonary inflammation that may lead to capillary leak. Finally, they play an important role in the regulation of alveolar fluid clearance. The present paper considers the pathways by which CAs contribute to the development of PO of various origin.
Keywords: nitric oxide (NO), high altitude pulmonary oedema (HAPE), capillary permeability, Acute respiratory distress syndrome (ARDS), right ventricular systolic pressure (RVSP), Inflammation, Cytokines
Cardiovascular & Hematological Disorders-Drug Targets
Title: The Role of Catecholamines in Formation and Resolution of Pulmonary Oedema
Volume: 7 Issue: 1
Author(s): Beate Rassler
Affiliation:
Keywords: nitric oxide (NO), high altitude pulmonary oedema (HAPE), capillary permeability, Acute respiratory distress syndrome (ARDS), right ventricular systolic pressure (RVSP), Inflammation, Cytokines
Abstract: Pulmonary oedema (PO) can emerge from mechanical disorders in pulmonary circulation leading to elevated fluid filtration in the lung, or from increased vascular permeability due to inflammatory or toxic injury of the alveolarcapillary barrier. A number of these disorders causing PO is associated with increased catecholamine (CA) levels in plasma and lung tissue and/or increased sympathetic activation such as neurogenic PO, high-altitude PO or PO in patients with phaeochromocytoma. Experimental CA stimulation in animals induced PO after less than one hour of infusion. Both α- and β-adrenergic mechanisms are involved in the pathogenesis but also in the resolution of PO. CAs increase pulmonary capillary pressure and thus, enhance fluid filtration into the pulmonary interstitium. Additionally, by activation of proinflammatory cytokines, they induce pulmonary inflammation that may lead to capillary leak. Finally, they play an important role in the regulation of alveolar fluid clearance. The present paper considers the pathways by which CAs contribute to the development of PO of various origin.
Export Options
About this article
Cite this article as:
Rassler Beate, The Role of Catecholamines in Formation and Resolution of Pulmonary Oedema, Cardiovascular & Hematological Disorders-Drug Targets 2007; 7 (1) . https://dx.doi.org/10.2174/187152907780059038
DOI https://dx.doi.org/10.2174/187152907780059038 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coronary Artery Bypass Graft in HIV-Infected Patients: A Multicenter Case Control Study
Current HIV Research Meet Our Editorial Board Member
Current Vascular Pharmacology Perinatal and Neonatal Outcomes of Lithium-Treated and Untreated Bipolar Women During Pregnancy: A Review of Present Literature
Current Psychopharmacology Proteomics to Identify Novel Biomarkers and Therapeutic Targets in Cardiovascular Disease
Letters in Drug Design & Discovery Light-at-Night-Induced Circadian Disruption, Cancer and Aging
Current Aging Science Clinical Profile of Relaxin, a Possible New Drug for Human Use
Current Drug Safety Fibrates in the Chemical Action of Daunorubicin
Current Cancer Drug Targets The Role of Combined Assessment of Defense Against Oxidative Stress and Inflammation in the Evaluation of Peripheral Arterial Disease
Current Molecular Medicine Hypertension and Concurrent Arrhythmias
Current Pharmaceutical Design The Fibroblast Growth Factor 23: A New Player in the Field of Cardiovascular, Bone and Renal Disease
Current Vascular Pharmacology Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy
Current Pharmaceutical Design Anti-platelet Drug-loaded Targeted Technologies for the Effective Treatment of Atherothrombosis
Current Drug Targets Human Embryonic Stem Cell-Derived Cardiomyocytes for Heart Therapies
Cardiovascular & Hematological Disorders-Drug Targets Bromodomain-Containing Protein 4: A Druggable Target
Current Drug Targets Pharmacotherapy of Mixed Dyslipidemia in the Metabolic Syndrome
Current Clinical Pharmacology Novel Molecular Targets in the Treatment of Cardiac Hypertrophy
Recent Patents on Cardiovascular Drug Discovery Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets Preface
Current Topics in Medicinal Chemistry A Comprehensive Literature Review of COPD-Related Fatigue
Current Respiratory Medicine Reviews Soluble Amyloid-β Levels and Late-Life Depression
Current Pharmaceutical Design